Arcellx, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rami Elghandour
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 25 West Watkins Mill Road Redwood City MD United States of America 20878
- IPO Date
- Feb 4, 2022
- CIK
- 0001786205
- Website
- arcellx.com
- Similar Companies
- Business
- Arcellx, Inc. Arcellx, Inc. (ACLX) is a clinical-stage biotechnology company developing innovative cell therapies powered by proprietary D-Domain binding technology, ddCAR platform, and ARC-SparX platform for patients with cancer and autoimmune diseases including multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, solid tumors such as hepatocellular carcinoma and small cell lung cancer, and generalized myasthenia gravis. Core products in its pipeline include anitocabtagene autoleucel (anito-cel, formerly CART-ddBCMA), a BCMA-targeted CAR-T cell therapy in Phase 3 iMMagine-3 and Phase 2 iMMagine-1 trials for relapsed or refractory multiple myeloma; ACLX-001, a dosable and controllable ARC-SparX therapy targeting BCMA for relapsed or refractory multiple myeloma; ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome; and additional preclinical programs targeting AML/MDS antigens, solid tumors, and non-oncology indications. Founded in 2014 and headquartered in Redwood City, California, with facilities in Rockville, Maryland, the company operates primarily in the United States and focuses on hematologic malignancies and high-unmet-need oncology areas through genetically engineered T cells designed for enhanced safety, efficacy, and accessibility. Recent developments include dosing completion in the iMMagine-1 trial and advancement toward a potential 2026 U.S. launch of anito-cel in partnership with Kite, a Gilead Company, following their 2022 global collaboration to co-develop and co-commercialize the asset; FDA clearance of an IND for a CD33/CD123-targeted ARC-SparX program in AML; initiation of a Phase 1 trial of anito-cel in generalized myasthenia gravis; and Q3 2025 financial results reflecting collaboration revenue from ongoing Kite partnership amid completion of anito-cel manufacturing in late 2024.
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Hold” by Analysts
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Banque Pictet & Cie SA Acquires Shares of 5,109 Arcellx, Inc. $ACLX
Gilead Extends Tender Offer to Acquire Arcellx
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—ACLX, VRE, EHAB, and CECO
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of “Hold” from Analysts
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders
Top 2 Health Care Stocks That May Crash This Quarter
Baron Health Care Fund Q4 2025 Contributors And Detractors
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement